Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Product Development

Regeneron aims to extend Eylea franchise as high-dose aflibercept hits in Phase III

Commercial success will depend on physician willingness to switch to high-dose aflibercept in increasingly competitive market

September 8, 2022 10:08 PM UTC

Regeneron is hoping to stave off coming biosimilar competition for blockbuster eye therapy Eylea with a high-dose formulation of aflibercept that showed non-inferior efficacy at dosing intervals of up to 16 weeks. But whether doctors are willing to switch patients to a regimen that extends the dosing interval by 1-2 months will determine how large the revenue tail is for the aflibercept franchise.

Investors added $12 billion to the market cap of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Thursday after the large cap reported positive data from the Phase III PHOTON and PULSAR trials that showed aflibercept 8 mg given at either 12- or 16-week intervals was non-inferior on the primary endpoint of mean observed best corrected visual acuity (BCVA) improvement vs. the marketed 2 mg dose of Eylea aflibercept administered as an 8-week regimen. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article